There is a new emphasis being placed on the “value of care” when making recommendations about what services and treatments should be covered by insurance. These decisions could ultimately lead to gaps in coverage and limited access for patients. We believe that “value” should first and foremost be considered through the eyes of patients who are the ultimate beneficiaries of health care. We have been a leading voice on this issue.
The Institute for Clinical and Economic Review issued a report called Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and ValueBased Price Benchmarks in September of 2016. Throughout the process, Lung Cancer Alliance and others provided comments and insights on behalf of the lung cancer community.
As a member of the Partnership to Improve Patient Care (PIPC) we have authored an OpEd on this subject that appeared in Morning Consult at the end of 2016.